RealTime Dynamix™: Inflammatory Bowel Disease US Q3 2018 Spotlight
Pfizer’s Xeljanz begins to shift the treatment paradigm in ulcerative colitis (UC) with early launch metrics largely favorable for the brand. The majority of patients started on Xeljanz have failed multiple biologics, but some gastroenterologists see the brand securing a role in the pre-biologic space in the near future, according to the latest quarterly report from Spherix Global Insights. See complimentary data highlights from the Q3 2018 wave of RealTime Dynamix™: Inflammatory Bowel Disease US below.
Contact [email protected] for more information about the highlighted report or to see if your company already has access to the report series.
All company, brand or product names and logos in this document are trademarks of their respective holders.